Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in... (GlobeNewswire EN) +++ ZEALAND PHARMA Aktie +3,28%

News zum Sektor Gesundheit aus Australien

Zum Sektor Gesundheit gehören Unternehmen der Pharmaka- & Biotechnologiebranche, Produzenten von medizintechnischen Geräten, Gesundheitsdienste, Kliniken und Pflegeeinrichtungen.
 >Gesundheit ETFs & Fonds 
Es sind 101 ETFs & Fonds zum Sektor Gesundheit bekannt.
 >Aktien zum Sektor Gesundheit 
Es sind 1531 Aktien zum Sektor Gesundheit bekannt.
 
07.10.26 - 13:48
Galliford Try, Quantum Blockchain, Futura Medical, Helix Exploration, 88 Energy, Powerhouse Energy - Small Cap Snapshot (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
07.10.26 - 04:12
Telix Pharmaceuticals: US-Marktstart für Hirntumor-Diagnostikum treibt Aktie an (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
07.10.26 - 03:00
AGL, Cochlear, WiseTech shares: Buy, hold, sell (Fool)
 
Find out what brokers expect next for these ASX shares. The post AGL, Cochlear, WiseTech shares: Buy, hold, sell appeared first on The Motley Fool Australia....
06.10.26 - 21:12
Healius vs Australian Clinical Labs: Which ASX pathology share wins? (Fool)
 
Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum. The post Healius vs Australian Clinical Labs: Which ASX pathology share wins? appeared first on The Motley Fool Australia....
06.10.26 - 12:33
First Patients Dosed with Telix′s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18) (GlobeNewswire EN)
 
MELBOURNE, Australia and INDIANAPOLIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patients in the United States (U.S.) have been dosed with Pixclara® (floretyrosine F 18 or 18F-FET), its FDA-approved, amino acid positron emission tomography (PET) drug for glioma (brain cancer) imaging....
06.10.26 - 06:12
Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value? (Fool)
 
Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my pick for value. The post Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value? appeared first on The Motley Fool Australia....
06.10.26 - 03:36
CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October? (Fool)
 
Can the CSL share price rebound keep going? The post CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October? appeared first on The Motley Fool Australia....
06.10.26 - 01:12
Are CSL shares a buy after its big news? (Fool)
 
I look at what CSL's latest drug development deal could mean for the healthcare giant's long-term growth. The post Are CSL shares a buy after its big news? appeared first on The Motley Fool Australia....
05.10.26 - 13:06
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson′s Disease and Movement Disorders (GlobeNewswire EN)
 
ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate ...
05.10.26 - 08:18
CSL strikes $1.55B lixudebart deal with Alentis for rare kidney and liver diseases (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.10.26 - 05:30
Monday′s HotCopper trends: Normandy Minerals, Optiscan Imaging, Imugene and other daily topics (Market Herald)
 
With more than 600k average monthly users on the HotCopper forums, each…...
05.10.26 - 03:30
CSL, Alentis Therapeutics Partner On Lixudebart In Deal Worth Up To $1.6 Bln (AFX)
 
CANBERA (dpa-AFX) - CSL (CSL.AX) and Alentis Therapeutics have entered into an exclusive global collaboration and co-promotion agreement to advance lixudebart, a potential first-in-class therapy t......
05.10.26 - 03:06
CSL investiert bis zu 1,6 Mrd. Dollar in Medikament gegen seltene Krankheiten – Aktie legt zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
05.10.26 - 02:57
CSL to pay up to $1.6 bln to develop rare disease drug; shares rise (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
05.10.26 - 01:12
ResMed vs Fisher & Paykel Healthcare: Which is better value? (Fool)
 
How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here's my verdict on which is the better buy. The post ResMed vs Fisher & Paykel Healthcare: Which is better value? appeared first on The Motley Fool Australia....
05.10.26 - 01:01
CSL teams up with Swiss Alentis for kidney and liver drug in A$2B deal (Market Herald)
 
CSL Ltd (ASX:CSL) has announced it's teaming up with Basel-headquartered Alentis Therapeutics…...
05.10.26 - 01:00
CSL unveils exclusive Alentis deal to advance rare disease treatments (Fool)
 
CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy. The post CSL unveils exclusive Alentis deal to advance rare disease treatments appeared first on The Motley Fool Australia....
05.10.26 - 00:45
CSL strikes $1.6B deal with Alentis for experimental kidney, liver drug (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.10.26 - 00:06
CSL Agrees to Pay Up to $1.6 Billion in Rare Disease Drug Deal (Bloomberg)
 
CSL Ltd. agreed to pay as much as $1.6 billion to jointly develop and sell an experimental treatment for rare kidney and liver diseases, expanding the Australian biotech company's push into kidney medicine....
04.10.26 - 23:45
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases (PR Newswire)
 
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Mann der Arbeit, aufgewacht und erkenne deine Macht. Alle Räder stehen still wenn dein starker Arm es will. - Georg Herwegh
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!